Loading
MiniMed Group, Inc. Stock: price and insider trades · United States
US·Mcap US$4.7B
MiniMed Group, Inc.: what insiders have been doing
Every trade that managers of MiniMed Group, Inc. disclose to SEC (Form 4) is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 36 filings came from 15 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of MiniMed Group, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 36 filings here.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
36
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate MiniMed Group, Inc. Buy (bullish), based on 15 analysts. Average price target: US$25.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,586 of 24,161 companies
26.7
score / 100
Value18
Quality35
FCF yld-8.5%
Earn yld-6.8%
EV/EBITDA·
ROE-8.7%
Gross mgn54%
Net mgn-11%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended April 2026 · cache
US$16.81
Analyst consensus
15 analystsBuy
US$15.00Target US$25.00(+49%)US$30.00
Income statement
RevenueUS$3.1B
Gross profitUS$1.7B54% margin
EBITDA-US$3M-0% margin
Net income-US$333M-9.7% margin
Valuation
PER (forward)24.3x
P/Book1.3x
Balance sheet & cash
Market capUS$4.7B
Total debtUS$145M
Free Cash Flow-US$420M
Debt / Equity2%
Profitability & ownership
ROE-8.7%
% insiders89.9%
% institutions13.6%
Last declaration on 16 October 2026
Declarations36 total
11,877 shares0Common StockSEC:0002114165-26-000002:0
3,374 shares0Common StockSEC:0001532133-26-000006:0
11,877 shares0Common StockSEC:0002158778-26-000004:0
252,813,348 sharesCommon StockSEC:0001999371-26-022968:0
11,795 shares0Common StockSEC:0001339919-26-000002:0
11,795 shares0Common StockSEC:0001218702-26-000003:0
11,795 shares0Common StockSEC:0001222831-26-000015:0
11,795 shares0Common StockSEC:0001468818-26-000004:0
11,795 shares0Common StockSEC:0001532133-26-000004:0
58,939 shares0Common StockSEC:0001995298-26-000009:0
31,350 shares@ US$18.150.035% mcap88.0% of flowCommon StockSEC:0001756652-26-000004:0
8,012 shares@ US$18.150.0089% mcap100.0% of flowCommon StockSEC:0002111492-26-000004:0
1,762 shares@ US$18.150.0019% mcap100.0% of flowCommon StockSEC:0002110477-26-000004:0
2,099 shares@ US$17.670.0023% mcap100.0% of flowCommon StockSEC:0002111466-26-000004:0
23,301 shares@ US$17.670.025% mcap100.0% of flowCommon StockSEC:0002111465-26-000004:0
14,705 shares0Common StockSEC:0002111466-26-000002:1
29,483 shares0Common StockSEC:0002111466-26-000002:0
36,762 shares0Common StockSEC:0002111492-26-000002:1
22,057 shares0Common StockSEC:0002110477-26-000002:1
94,550 shares0Common StockSEC:0002111465-26-000002:0
22,057 shares0Common StockSEC:0002111465-26-000002:1
297,618 shares0Common StockSEC:0001756652-26-000002:0
94,550 shares0Common StockSEC:0002111492-26-000002:0
24,244 shares0Common StockSEC:0001850688-26-000003:0
60,730 shares0Common StockSEC:0002110477-26-000002:0
25 of 36 declarations
About MiniMed Group, Inc.
MiniMed Group, Inc. is a NASDAQ-listed company that specializes in developing technologies for diabetes management. It focuses on glucose monitoring systems and insulin pumps.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
